Nuvalent, Inc. (NUVL) FY2025 10-K Annual Report
Nuvalent, Inc. (NUVL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Nuvalent, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model focused on biopharmaceutical development and innovation
- • No new products, services, or segments introduced or emphasized this year
Management Discussion & Analysis
- • Net loss $425.4M in 2025 vs $260.8M in 2024; operating cash outflow $275.2M vs $185.1M
- • Operating cash flow decline due to higher clinical, manufacturing, personnel expenses; stock-based comp $86.5M vs $60.6M
Risk Factors
- • FDA acceptance of NDA for zidesamtinib with PDUFA date September 18, 2026, critical regulatory milestone risk
- • Exposure to macroeconomic risks including inflation, interest rate fluctuations, and geopolitical tensions impacting funding access
Nuvalent, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$425M
▼ -63.1% YoY
ROE
-34.1%
▼ -970bp YoY
Total Assets
$1.4B
▲ +23.7% YoY
EPS (Diluted)
$-5.85
▼ -48.9% YoY
Operating Cash Flow
-$275M
▼ -48.7% YoY
Source: XBRL data from Nuvalent, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nuvalent, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.